Login / Signup

Sustained sutimlimab response for 3 years in patients with cold agglutinin disease: A phase I, open-label, extension trial.

Georg GelbeneggerUlrich JaegerMichael FillitzShirley D'SaRonwyn CartwrightFrank ShaferMarek WardȩckiJennifer WangChristian SchoergenhoferBernd Jilma
Published in: British journal of haematology (2022)
Keyphrases
  • open label
  • phase iii
  • phase ii
  • study protocol
  • clinical trial
  • phase ii study
  • randomized controlled trial
  • double blind
  • placebo controlled